ASNase treatment, which depletes plasma glutamine in addition to asparagine, is also likely to show some efficacy in tumours lacking GS, although alternative means of depleting plasma glutamine by using phenylacetate have previously been trialled, albeit without stratification of patients for GS expression status.13,14 Interestingly, stromal cell expression of GS may also be important for cancer growth, suggesting that targeting this mechanism may indirectly reduce tumour cell proliferation.15 The gene discussed is GLUL; the disease is neoplasm.